scholarly journals The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007‐2017

2021 ◽  
Author(s):  
James M. Paik ◽  
Pegah Golabi ◽  
Youssef Younossi ◽  
Nazaneen Saleh ◽  
Annan Nhyira ◽  
...  
Author(s):  
Shu-Zhen Zhang ◽  
Long Xie ◽  
Zheng-Jun Shang

Background: Oral cancer (OC) is a common tumour that poses a threat to human health and imposes a heavy burden on countries. This study assessed the burden imposed by OC on the 10 most populous countries from 1990 to 2019 on the basis of gender, age and socio-demographic index. Methods: Data on incidence, mortality, disability-adjusted life years (DALY) and corresponding age-standardised rates (ASR) for OC in the 10 most populous countries from 1990 to 2019 were derived from the Global Burden of Disease Study 2019. Estimated annual percentage changes were calculated to assess the trends of morbidity, mortality and DALY. The indicator that served as a proxy for survival rate was the supplement of mortality-to-incidence ratio (SMIR) (1 − (M/I)). Results: The number of new cases, deaths and DALY have increased in all 10 countries in the past 30 years. Trends in age-standardised incidence rates (ASIR), age-standardised mortality rate (ASMR) and age-standardised DALY for OC in the 10 most populous countries varied. The SMIR increased in all countries, with most countries having an SMIR between 30% and 50%. In 2019, the United States had the highest SMIR at 76%, whereas Russia had the lowest at 21.7%. Incidence and mortality were close between male and female subjects in Japan, Indonesia, Mexico, India, Bangladesh and Pakistan. The incidence and mortality in male subjects in the United States, Russia, China and Brazil were two or more times those of female subjects. Gender difference was highest among patients aged 40–69 years. Conclusion: Trends and gender differences in ASIR, ASMR and age-standardised DALY for OC vary in the 10 most populous countries. Government cancer programs are often expensive to run, especially in countries with large populations. Policy makers need to take these differences into account when formulating policies.


2011 ◽  
Vol 9 (10) ◽  
pp. 834-841 ◽  
Author(s):  
Andres F. Carrion ◽  
Ravi Ghanta ◽  
Olveen Carrasquillo ◽  
Paul Martin

2017 ◽  
Vol 112 (11) ◽  
pp. 1700-1708 ◽  
Author(s):  
Natsu Fukui ◽  
Pegah Golabi ◽  
Munkhzul Otgonsuren ◽  
Alita Mishra ◽  
Chapy Venkatesan ◽  
...  

2020 ◽  
Author(s):  
Di Lu ◽  
Jintao Zhan ◽  
Xiguang Liu ◽  
Xiaoying Dong ◽  
Siyang Feng ◽  
...  

Abstract Background: Esophageal cancer is the 7th leading cancer globally and the 10th leading cancer in the United States. However, it is has received limited attention over more common malignancies. Only a few studies have comprehensively assessed disease burden from esophageal cancer in the United States (US). Methods: Using states-categorized data on incidence, mortality, and Disability-adjusted Life Years (DALYs), this study analyzed the current trends in esophageal cancer disease burden. Data and risk factor indicators were obtained from Global Burden of Disease (GBD) online resource and used to determine annual relative change. Results: We report here that between 1990 and 2017, the number of esophageal cancer new cases, deaths and DALYs in the US increased significantly, while the Age-standardized Rate (ASR) of disease incidence remained constant. During the same time, disease burden from esophageal cancer in males was higher than that in females. Economically stronger states trend to had lesser disease burden from esophageal cancer. Smoking and alcohol use contributed most of the burden while influence of high body-mass index and diet low in fruits grew largely. Conclusions: This study provided an analysis of esophageal cancer disease burden in the United States that will inform the design of targeted strategies for disease prevention tailored to different states.


PEDIATRICS ◽  
1992 ◽  
Vol 89 (4) ◽  
pp. 795-800 ◽  
Author(s):  

HEPATITIS B DISEASE AND EPIDEMIOLOGY In the United States 200 000 to 300 000 acute infections with hepatitis B virus (HBV) occur each year.1,2 More than one million persons in the United States have chronic HBV infection, and approximately 4000 to 5000 persons die each year from HBV-induced chronic liver disease and hepatocellular carcinoma. Although HBV infections occur during childhood and adolescence, the full impact of these infections is not recognized until many years later when chronic liver disease and hepatocellular carcinoma may develop. The incidence of HBV infection increases rapidly during adolescence, with higher rates among blacks than among whites (Fig 1).3 Although rates vary by region, sex, and race, between 3.3% and 25% of all persons have had HBV infection by 25 to 34 years of age. The likelihood of becoming chronically infected with HBV varies inversely with the age at which infection occurs. HBV transmitted from hepatitis B surface antigen (HBsAg)-positive mothers to their newborns results in HBV carriage for up to 90% of infants. Between 25% and 50% of children infected before 5 years of age become carriers, whereas only 6% to 10% of acutely infected adults become carriers. It is estimated that more than 25% of carrier infants will die from primary hepatocellular carcinoma or cirrhosis of the liver, with most of these deaths occurring during adult life. HBV infection occurs more commonly in certain populations, including Pacific Islanders, Alaskan Natives, immigrants from countries in which infection is highly endemic, persons who require multiple transfusions of blood or blood products, and persons with high-risk lifestyles, including intravenous drug abuse and contact with multiple sexual partners.


Sign in / Sign up

Export Citation Format

Share Document